Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), will participate in two upcoming investor conferences.

Rhea-AI Summary

Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), will participate in two upcoming investor conferences. The first is the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, featuring a fireside chat at 10:55 am ET. The second is the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, with a fireside chat at 10:00 am ET. Both sessions will be accessible via webcast on Altimmune's website. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with notable products like pemvidutide (ALT-801).

Argus Session date unavailable

+6.52% session move Open Argus

Details

News Market Reaction – ALT

The recorded move for ALT in the trading session of this news was +6.52%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences:

• Evercore ISI 5^th Annual HealthCONx Virtual Conference
  Tuesday, November 29, 2022
  Fireside chat at 10:55 am Eastern Time

• Piper Sandler 34^th Annual Healthcare Conference in New York, NY
  Thursday, December 1, 2022
  Fireside chat at 10:00 am Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences is Altimmune participating in?

Altimmune is participating in the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, and the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022.

What is the date and time of Altimmune's presentation at the Evercore ISI conference?

Altimmune's fireside chat at the Evercore ISI conference is scheduled for November 29, 2022, at 10:55 am Eastern Time.

When will Altimmune's presentation at the Piper Sandler conference take place?

Altimmune's fireside chat at the Piper Sandler conference will occur on December 1, 2022, at 10:00 am Eastern Time.

Where can I access the webcasts of Altimmune's investor conference presentations?

The webcasts of Altimmune's investor conference presentations can be accessed on the Events section of the Altimmune website.

What is Altimmune's lead product candidate?

Altimmune's lead product candidate is pemvidutide (ALT-801), a GLP-1/glucagon dual receptor agonist being developed for obesity and NASH.